Results 41 to 50 of about 5,494 (193)

Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab

Frontiers in Aging Neuroscience, 2022
Alzheimer’s disease (AD) is the most prevalent form of age-related dementia in the world, and its main pathological features consist of amyloid-β (Aβ) plaque deposits and neurofibrillary tangles formed by hyperphosphorylated tau protein.
Mingchao Shi, Fengna Chu, Feiqi Zhu, Jie Zhu, Jie Zhu   +4 more
doaj   +1 more source

Is Aducanumab a Miracle Drug?

Journal of Student Research, 2022
A new drug called Aducanumab has been circulating the medical news for a while along with many questions. To answer these questions, it is imperative to understand Alzheimer’s disease.  This research was done by reading other articles and observing scans to truly comprehend the premise of the problems.
Sanjana Ananthula, Rajagopal Appavu, Josthana Kethar   +2 more
openaire   +1 more source

Alzheimer's disease drug development pipeline: 2022

Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2022
Introduction Alzheimer's disease (AD) represents a global health crisis. Treatments are needed to prevent, delay the onset, slow the progression, improve cognition, and reduce behavioral disturbances of AD. We review the current clinical trials and drugs
Jeffrey Cummings, Garam Lee, Pouyan Nahed, Mina Esmail Zadeh Nojoo Kambar, Kate Zhong, Jorge Fonseca, Kazem Taghva   +6 more
doaj   +1 more source

Development of monoclonal antibody therapeutics for alzheimer's disease

Taiwanese Journal of Psychiatry, 2022
Background: In a previous review article in the Taiwanese Journal of Psychiatry (Takeda and Tagami: Taiwanese J. Psychiatry 2020; 34: 152-61), we gave the development status of drugs for Alzheimer's disease, presented a relatively pessimistic view, and ...
Masatoshi Takeda
doaj   +1 more source

El caso de aducanumab ¿Más esperanza que ciencia?

ARS Medica, 2021
En junio, la Agencia de Alimentos y medicamentos de los Estados Unidos (FDA) otorgó aprobación mediante vía acelerada al medicamento aducanumab, desarrollado por Biogen, Inc.  para tratamiento de la enfermedad de Alzheimer (EA).  Esta autorización no ha
Eliana Sánchez-Montoya, Max Andresen, Raúl Corrales, Jorge Gallardo, Viviana Noriega, Caroline R. Weinstein-Oppenheimer   +5 more
doaj   +1 more source

Aducanumab therapy to treat Alzheimer\u27s disease: A narrative review

, 2022
Background. Aducanumab, a new monoclonal antibody that targets β-amyloid aggregates, has been granted conditional approval by the U.S. FDA for treatment of mild Alzheimer\u27s disease (AD).
Beshir, Semira Abdi, Menon, Vineetha Bharathan, Parveen, Affana, Hussain, Nadia, Goh, Sheron Sir Loon, Aadithsoorya, A.M.   +5 more
core   +1 more source

Aducanumab-Related Amyloid-Related Imaging Abnormalities: Paean or Lament? [PDF]

, 2022
When the FDA granted accelerated approval of Biogen's Alzheimer disease drug, aducanumab (marketed as Aduhelm), it deviated from its mission of guaranteeing drug safety and efficacy because the approval was based exclusively on a perceived dose-dependent
Alavi, Abass, Høilund-Carlsen, Poul F., Werner, Thomas J., Revheim, Mona-Elisabeth, Revheim, Mona Elisabeth   +4 more
core   +1 more source

Aducanumab: a decade in the making and a hopeful tactic for addressing alzheimer’s [PDF]

Brazilian Journal of Pharmaceutical Sciences
Alzheimer’s disease, one of the most prevalent neurodegenerative disorders affecting millions globally, presents significant cognitive challenges. Evidence suggests that amyloid-beta (Aβ) accumulation plays a central role in the disease's progression ...
Rohith Gollapudi, Vijaya Medabalimi, Satya Mounika Nallam, Aravinda Sai Kolusu, Venkateswara Raju Kalidindi, Pavan Kumar Samudrala   +5 more
doaj   +2 more sources

A narrative review on preclinical/clinical trials on aducanumab [PDF]

Scripta Medica
The most widespread type of dementia, Alzheimer's disease (AD), is predicted to triple in global prevalence by 2050. AD has a substantial societal and economic impact across the world, negatively affecting both patients and their caregivers, as the ...
Goel Akriti, Garima, Jain Paras, Bansal Seema, Chopra Hitesh, Gupta Sumeet, Kumar Satish, Dhanawat Meenakshi, Aggarwal Navidha   +8 more
doaj   +1 more source

Comparison of safety of lecanemab and aducanumab: a real-world disproportionality analysis using the FDA adverse event reporting system

Frontiers in Pharmacology
ObjectiveStudies on anti-Aβ drugs for the treatment of Alzheimer’s disease (AD) have garnered significant attention; however, their safety still requires further research and monitoring. Although recent studies have analyzed the adverse drug events (ADEs)
Lingti Kong, Lingti Kong, Lingti Kong, Xiaohu Yang, Xiaohu Yang, Jian Xu, Jian Xu   +6 more
doaj   +1 more source